Who is sponsoring NCT03564054?

NCT03564054 is sponsored by University of Florida.

What drugs are being tested in NCT03564054?

Interventions in NCT03564054: Photodynamic Therapy, Argon Plasma Coagulation.

What condition does NCT03564054 study?

NCT03564054 studies Non Small Cell Lung Cancer.

Is NCT03564054 still recruiting?

NCT03564054 is currently terminated. Last updated 18 December 2019.

Last reviewed 2019-12-18 · How we verify

NCT03564054

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction

Terminated NA Last updated 18 December 2019

What this trial tests

NA trial testing Photodynamic Therapy in Non Small Cell Lung Cancer in 3 participants. Terminated before completion.

Timeline

11 October 2018

Primary endpoint
30 September 2019

30 September 2019

Quick facts

Lead sponsor	University of Florida
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	11 October 2018
Primary completion	30 September 2019
Estimated completion	30 September 2019
Sites	1 location across United States

Drugs / interventions tested

Photodynamic Therapy — full drug profile →
Argon Plasma Coagulation

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

University of Florida

Who can join

Adults 18 to 99, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the efficacy of photodynamic therapy (PDT) in relieving airway obstruction in subjects with lung cancer compared to treatment with argon plasma coagulation (APC).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis.
Ren Y, Wang R, Weng S, Xu H, et al · · 2023 · cited 87× · PMID 37563639 · DOI 10.1186/s12943-023-01831-w
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.
Penetra M, Arnaut LG, Gomes-da-Silva LC. · · 2023 · cited 36× · PMID 37346450 · DOI 10.1080/2162402x.2023.2226535
Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.
Yu L, Berner J, Martinet A, Freund E, et al · · 2025 · PMID 41008962 · DOI 10.3390/antiox14091055

Verify or expand the search:

Other trials of Photodynamic Therapy

Trials testing the same drug.

NCT07254260 — Photodynamic Therapy and Post-Endodontic Pain in Undergraduate-Performed Treatments · completed
NCT06381154 — Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or · Phase 2 · recruiting
NCT06307548 — Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in P · Phase 1, PHASE2 · suspended
NCT06752343 — A Comparison of Photodynamic Therapy and Topical Clobetasol in Treatment of Oral Lichen Planus: a Split-Mouth Randomised · Phase 2 · completed
NCT05676801 — Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-III) · EARLY_PHASE1 · unknown

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03564054 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 18 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03564054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing